Rockford Center

rockfordcenter.com

Rockford Center is a 138-bed mental health facility located in Newark, DE, providing easy access to a full complement of inpatient and partial behavioral health programs for children and adolescents, adults, and older adults. The mission of Rockford Center is to serve the needs of our regions mental health consumers by offering all of our patients and families outstanding healthcare services that are consistently trauma responsive, empowering and respectful, and which promote and sustain recovery. This critical mission is accomplished by working in partnership with individuals, families, healthcare providers, and other community stakeholders.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE

Pfizer | August 17, 2021

news image

Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...

Read More

Business Insights

ADARE PHARMA SOLUTIONS ACQUIRES FRONTIDA BIOPHARM TO EXPAND LEADING CDMO OFFERINGS

Adare Pharma Solutions | December 02, 2021

news image

Adare Pharma Solutions ("Adare"), a technology-driven contract development and manufacturing organization (CDMO), announced the acquisition of Frontida BioPharm ("Frontida"), a vertically integrated CDMO focused on oral formulations. The acquisition reinforces Adare's commitment to transform drug delivery by providing world class solutions from product development through commercial scale manufacturing and packaging. Adare's portfolio of offerings for its custom...

Read More

Business Insights, PHARMA TECH

KSQ ANNOUNCES ONO’S ACQUISITION OF MULTIPLE RESEARCH-STAGE ONCOLOGY PROGRAMS

KSQ Therapeutics | January 30, 2023

news image

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

Read More

Pharmacy Market

MARINUS PHARMACEUTICALS ANNOUNCES NEW METHOD OF USE PATENT GRANTED FOR IV GANAXOLONE BY USPTO IN STATUS EPILEPTICUS

Businesswire | June 26, 2023

news image

Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including t...

Read More
news image

Pharmacy Market

PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE

Pfizer | August 17, 2021

Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...

Read More
news image

Business Insights

ADARE PHARMA SOLUTIONS ACQUIRES FRONTIDA BIOPHARM TO EXPAND LEADING CDMO OFFERINGS

Adare Pharma Solutions | December 02, 2021

Adare Pharma Solutions ("Adare"), a technology-driven contract development and manufacturing organization (CDMO), announced the acquisition of Frontida BioPharm ("Frontida"), a vertically integrated CDMO focused on oral formulations. The acquisition reinforces Adare's commitment to transform drug delivery by providing world class solutions from product development through commercial scale manufacturing and packaging. Adare's portfolio of offerings for its custom...

Read More
news image

Business Insights, PHARMA TECH

KSQ ANNOUNCES ONO’S ACQUISITION OF MULTIPLE RESEARCH-STAGE ONCOLOGY PROGRAMS

KSQ Therapeutics | January 30, 2023

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

Read More
news image

Pharmacy Market

MARINUS PHARMACEUTICALS ANNOUNCES NEW METHOD OF USE PATENT GRANTED FOR IV GANAXOLONE BY USPTO IN STATUS EPILEPTICUS

Businesswire | June 26, 2023

Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us